_5-year-follow-up-results-of-cll14-obinutuzumab-venetoclax-vs-obinutuzumab-chlorambucil-in-cll-preview-1.jpg "5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL from obinutuzumab and venetoclax in cll Video Screenshot Preview 1")
Gallery_5-year-follow-up-results-of-cll14-obinutuzumab-venetoclax-vs-obinutuzumab-chlorambucil-in-cll-preview-3.jpg "5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL from obinutuzumab and venetoclax in cll Video Screenshot Preview 3")
Gallery_5-year-follow-up-results-of-cll14-obinutuzumab-venetoclax-vs-obinutuzumab-chlorambucil-in-cll-preview-hqdefault.jpg "5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL from obinutuzumab and venetoclax in cll Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 59 seconds
👁 View: 352 times
Play Audio:👁 View: 352 times
Description:
VJHemOnc – Video Journal of Hematology u0026 HemOnc
VJHemOnc – Video Journal of Hematology u0026 HemOnc
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_cll14-venetoclax-plus-obinutuzumab-in-untreated-cll.webp "Dr Othman Al-Sawaf speaks to ecancer about the four-year follow-up of the CLL14 trial looking at venetoclax and obinutuzumab in untreated chronic lymphocyte leukaemia. nnDr Al Sawaf explains that venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia. In the CLL14 trial, the long-term efficacy after treatment cessation of the combination of venetoclax plus obinutuzumab with chlorambucil plus obinutuzumab was compare")
_six-year-update-from-cll14-fixed-duration-venetoclax-obinutuzumab-for-previously-untreated-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 43 seconds 👁 88
_6-year-results-of-cll14-venetoclax-obinutuzumab-for-previously-untreated-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 5 minutes 59 seconds 👁 828
_kirsten-fischer-new-fixed-duration-venetoclax-plus-obinutuzumab-in-previously-untreated-patients-with-cll.webp "Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and coexisting comorbidities (abstract S149)nPresenter: Dr Kirsten Fischer – Germany - Recorded @ EHA Press Briefing, Friday, June 14, 2019 @ RAI in AmsterdamnMore info @ https://oncoletter.ch")
⏲ 6 min 66 sec ✓ 14-Jun-2019
_venetoclax-obinutuzumab-impact-on-cll-management.webp "OncLiveTV")
_amy-pierre-anp-bc-on-cll-in-older-patients-the-alliance-trial-on-ibrutinib-obinutuzumab-and-venetoclax.webp "Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax from obinutuzumab and venetoclax in cll")
⏲ 1 min 41 sec ✓ 09-Dec-2019
_cll14-venetoclax-plus-obinutuzumab-for-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_cll-venetoclax-in-combination-with-obinutuzumab.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_cll14-venetoclax-plus-obinutuzumab-in-untreated-cll.jpg)
_six-year-update-from-cll14-fixed-duration-venetoclax-obinutuzumab-for-previously-untreated-cll.jpg)
_6-year-results-of-cll14-venetoclax-obinutuzumab-for-previously-untreated-cll.jpg)
_kirsten-fischer-new-fixed-duration-venetoclax-plus-obinutuzumab-in-previously-untreated-patients-with-cll.jpg)
_venetoclax-obinutuzumab-impact-on-cll-management.jpg)
_amy-pierre-anp-bc-on-cll-in-older-patients-the-alliance-trial-on-ibrutinib-obinutuzumab-and-venetoclax.jpg)
_cll14-venetoclax-plus-obinutuzumab-for-cll.jpg)
_cll-venetoclax-in-combination-with-obinutuzumab.jpg)
![[+]](/images/menu.gif){kind=small}